Status:
UNKNOWN
Neuroinflammation in Hypertension Study
Lead Sponsor:
Royal Perth Hospital
Conditions:
Resistant Hypertension
Eligibility:
All Genders
45-65 years
Phase:
PHASE3
Brief Summary
To demonstrate that in patients with resistant hypertension oral treatment with minocycline via inhibition of central immune cell activation and inflammation results in reduced central sympathetic out...
Detailed Description
This is a randomized, double-blind, placebo controlled, parallel group design study aiming to compare the effects of minocycline 100mg twice daily vs matched placebo for 12 weeks on ambulatory BP and ...
Eligibility Criteria
Inclusion
- Aged: 45 -65 years
- Signed informed consent
- Clinical diagnosis of Resistant Hypertension
- Daytime systolic ambulatory BP \>135mmHg.
Exclusion
- • eGFR of \<45 mL/min/1.73m2
- History of myocardial infarction (MI) or any cardiovascular event within 3 months of screening period, clinically significant AV conduction disturbances and/or arrhythmias,
- current of past history of heart failure (LVEF ≤40%)
- psychotropic agents, antidepressants and NSAIDS
- alcohol consumption of \>3 standard drinks.
- known hypersensitivity or contraindication to minocycline or other tetracyclines.
Key Trial Info
Start Date :
July 2 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2025
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04478500
Start Date
July 2 2020
End Date
February 1 2025
Last Update
September 29 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Royal Perth Hospital
Perth, Western Australia, Australia, 6000